Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
Your view on NERV
Overview
What the company does, where it operates, and who runs it.
About Minerva Neurosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Remy Luthringer
- Headquarters
- 1601 Trapelo Road, Burlington, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Remy Luthringer
- Headquarters
- 1601 Trapelo Road, Burlington, MA, US
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013.
Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Minerva Neurosciences, Inc. from FRC's valuation model, read against the market price. NERV last traded at $2.56; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Minerva Neurosciences, Inc.. Starting points for Minerva Neurosciences, Inc.: EPS -$5.90, beta -0.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Minerva Neurosciences, Inc.. Minerva Neurosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Minerva Neurosciences, Inc.. Trailing twelve-month EPS for Minerva Neurosciences, Inc. stands at -$5.90. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$10.00
Median
$10.00
High
$10.00
Average target · 1 new target in the last 3 months, average $10.00
Analyst Ratings
- Strong Buy0
- Buy5
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrJun 2020 | Next QtrMar 2021 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$2.32 | $2.66 | -$1.98 | -$0.67 |
| Low estimate | -$2.32 | $2.66 | -$1.98 | -$0.67 |
| High estimate | -$2.32 | $2.66 | -$1.98 | -$0.67 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | — | — | -$34.67 | — |
| Growth | — | — | +94.3% | — |
Revenue Estimate
| Revenue | Current QtrJun 2020 | Next QtrMar 2021 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $16.36M | $24.00M | $19.76M | $56.49M |
| Low estimate | $13.09M | $24.00M | $19.76M | $56.49M |
| High estimate | $19.63M | $24.00M | $19.76M | $56.49M |
| No. of analysts | 7 | 3 | 3 | 3 |
| Year-ago revenue | — | — | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Minerva Neurosciences, Inc.. Minerva Neurosciences, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Minerva Neurosciences, Inc. valued side by side against its closest peers. Minerva Neurosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Minerva Neurosciences, Inc., and how their positions are changing. At a $122.2M market value, institutional positions materially move Minerva Neurosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Minerva Neurosciences, Inc. executives and directors. Shares of Minerva Neurosciences, Inc. have traded between $1.15 and $12.46 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Minerva Neurosciences, Inc.. Coverage tracks Minerva Neurosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Minerva Neurosciences, Inc.